A Study of Sofosbuvir From Heterosofir 400 mg F.C.T (Pharmed Healthcare, Egypt) & Sovaldi 400 mg F.C.T ( Gilead Sciences, Ireland)

计划入组 24 人 · 首次发布于 2015 年 7 月 8 日

A Study of Sofosbuvir and Ledipasvir From Soviredia 90/400 mg Tablets (Minapharm, Egypt) Versus Harvoni 90/400 mg Tablets (Gilead Sciences, USA)

计划入组 30 人 · 首次发布于 2019 年 7 月 31 日

A Bio-equivalence Study of Sofosbuvir From Magicbuvir 400 mg Film Coated Tablets ( Magic Pharma, Egypt) Versus Sovaldi 400 mg Tablets (Gilead Sciences, Canada)

计划入组 36 人 · 首次发布于 2016 年 11 月 2 日

GS-441524, Gilead Sciences

PI3Kβ inhibitor(Gilead Sciences)

Epoetin alfa biosimilar (LG Life Sciences)

Gilead Sciences

United States

Gilead Sciences Inc

Spain

GILEAD SCIENCES SL

United States

Gilead Defends TDF Development Amidst Litigation, Cites Patient Needs and FDA Guidance

Roche's $1.5B Acquisition of Poseida Therapeutics Highlights Cell Therapy's Potential; Arovella Therapeutics (ALA) Poised for Phase 1 Trial

Gilead Sciences Showcases Innovative Therapies and R&D Expansion at CIIE